Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Current Standards of Care for Chemotherapy of Optimally Cytoreduced Advanced Epithelial Ovarian Cancer

Highlights

  • Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer.
  • Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in the setting of optimal residual advanced ovarian cancer.
  • The role of bevacizumab in the primary anti-neoplastic drug management of optimal residual advanced ovarian cancer remains to be defined.

Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer 

Maurie Markman

http://www.sciencedirect.com/science/article/pii/S0090825813007622

Abstract 

There has been limited change in evidence-based primary chemotherapeutic management of optimal residual advanced ovarian cancer for more than a decade. The backbone of therapy remains a platinum agent (generally carboplatin) and a taxane (generally paclitaxel). Phase 3 randomized trial data provide support for the use of weekly paclitaxel in this setting (compared to the traditional every 3-week schedule) and the addition of bevacizumab as a component of primary management. Recently available data provide increasingly solid support for a role of regional platinum administration in at least a subset of patients with optimal residual advanced ovarian cancer and an important retrospective analysis has suggested a novel biomarker that may predict for the utility (or lack thereof) of this method of drug delivery.

Information

This entry was posted on June 21, 2013 by in Research Updates and tagged , , , , .

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: